Knowledge Base
Explore foundational concepts, inspection readiness guides, and regulatory frameworks.
Recent Articles
Venlafaxine: Discovery, Development, Safety and Pharmacovigilance
An evidence-based account of venlafaxine's serotonin–noradrenaline pharmacology, depression and anxiety evidence, regional labels, dose-related blood-pressure risk, withdrawal syndromes, interactions and pharmacovigilance.
Tramadol: Discovery, Development, Safety and Pharmacovigilance
A lifecycle review of tramadol from Grünenthal development to current pharmacovigilance, integrating analgesic evidence, metabolism, respiratory depression, seizures, serotonin toxicity, dependence and regional label interpretation.
Venetoclax: Discovery, Development, Safety and Pharmacovigilance
A lifecycle review of venetoclax from selective BCL-2 discovery to modern combination regimens and their pharmacovigilance.
Ruxolitinib: Discovery, Development, Safety and Pharmacovigilance
An evidence-based lifecycle account of ruxolitinib, its pivotal trials, Incyte–Novartis development, evolving formulations and paediatric indications, myelosuppression, infections, treatment interruption and US/EU listedness.
Product Pharmacovigilance
230- Paracetamol: Discovery, Development, Safety and Pharmacovigilance
- Methylphenidate: Discovery, Development, Safety and Pharmacovigilance
- Lamivudine: Discovery, Development, Safety and Pharmacovigilance
- Duloxetine: Discovery, Development, Safety and Pharmacovigilance
- Aflibercept: Discovery, Development, Safety and Pharmacovigilance
EU Pharmacovigilance
90- GVP Module VI: Patient Support Programmes and Solicited Reports
- What Are EU Good Pharmacovigilance Practices (GVP)?
- Product Quality Complaints and Pharmacovigilance: Where the Systems Meet
- Pharmacovigilance in Older People: Geriatric Considerations
- Listedness, Expectedness and Reference Safety Information
Other
87- Venlafaxine: Discovery, Development, Safety and Pharmacovigilance
- Tramadol: Discovery, Development, Safety and Pharmacovigilance
- Venetoclax: Discovery, Development, Safety and Pharmacovigilance
- Ruxolitinib: Discovery, Development, Safety and Pharmacovigilance
- Pomalidomide: Discovery, Development, Safety and Pharmacovigilance
EU Regulatory Affairs
31- What Is CMDh? Role, Functions and Regulatory Significance in the EU Medicines System
- What Is a Marketing Authorisation in the EU?
- What Happens After a PRAC Recommendation? CHMP, CMDh and the European Commission
- What Happens When Member States Disagree During an MRP or DCP?
- What Does the Marketing Authorisation Holder Do During an EMA Referral?
Signal Management & Benefit-Risk
26- What Is a Safety Signal?
- Signal Tracking and Documentation
- Signal Validation in Pharmacovigilance
- Signal Management Oversight
- Signal Management SOPs
QPPV, Governance & PSMF
23- Pharmacovigilance Governance
- How to Become a QPPV
- What is a Local Safety Officer?
- QPPV Responsibilities
- UK QPPV Requirements
Signal Evaluation
16- Thalidomide and Congenital Malformations: A Historical Signal Evaluation
- Statins and Tendon Rupture: A Signal Evaluation
- Signal Evaluation: SSRIs and Persistent Pulmonary Hypertension of the Newborn
- SSRIs and Postpartum Haemorrhage: A Signal Evaluation
- Historical Signal Evaluation: Metamizole and Agranulocytosis
Risk Management Plans
14- Types of Risk Management Plans
- Safety Specification
- RMP Lifecycle Management
- RMP Governance and Version Control
- Risk Management Plans (RMPs)
Drug Safety
13- Teratogenicity in Pharmacovigilance
- Posterior Reversible Encephalopathy Syndrome (PRES) Associated With Medicinal Products
- Hy's Law: Identifying Potential Serious Drug-Induced Liver Injury
- eDISH: Evaluating Drug-Induced Serious Hepatotoxicity in Clinical Trials
- Drug-Induced Liver Injury (DILI): From Liver Test Abnormalities to Causality and Regulatory Safety Assessment
PBRER
12- How to Write a PBRER
- Understanding the Structure of a PBRER
- Writing the Executive Summary in a PBRER
- Writing the Worldwide Marketing Authorisation Status Section in a PBRER
- Writing the Overall Conclusion and Actions Section in a PBRER
Pharmacovigilance Inspections
11- What Is a QPPV Inspection?
- What Is a Pharmacovigilance Inspection?
- PSMF and Pharmacovigilance System Governance Findings: What EU Inspectors Test
- Pharmacovigilance Inspections
- Inspection Interviews in Pharmacovigilance
Medicinal Products
10- Valsartan: Discovery, Development, Safety and Pharmacovigilance
- Tafamidis: Discovery, Development, Safety and Pharmacovigilance
- Sertraline: Discovery, Development, Safety and Pharmacovigilance
- Osimertinib: Discovery, Development, Safety and Pharmacovigilance
- Enzalutamide: Discovery, Development, Safety and Pharmacovigilance
Audits & Quality Assurance
9- What Is CAPA in Pharmacovigilance?
- What Is a Pharmacovigilance Audit?
- Risk-Based Audit Planning in Pharmacovigilance
- QPPV and Audit Oversight
- Pharmacovigilance Audits
Vendor Management
9- Vendor Risk Assessment in Pharmacovigilance
- Vendor Oversight in Pharmacovigilance
- Vendor Qualification and Selection in Pharmacovigilance
- Common Vendor Oversight Inspection Findings
- Vendor KPIs and Metrics in Pharmacovigilance
Computerised System Validation
7- User Requirements Specifications (URS) in Pharmacovigilance
- Functional Specifications and Design Specifications in Pharmacovigilance
- Validation Testing in Pharmacovigilance: IQ, OQ, PQ and User Acceptance Testing
- Traceability Matrix in Computerised System Validation
- Computerised System Validation Plan
Safety Operations
7- XEVMPD Guide for Pharmacovigilance Professionals
- What Is EudraVigilance?
- Medical Literature Monitoring in Pharmacovigilance
- EudraVigilance Metrics and KPIs for QPPVs
- EudraVigilance Registration and Access Management
EU Pharmacovigilance Inspection Findings
6- EU Pharmacovigilance Inspection Findings: Lifecycle Management and Continuity of Pharmacovigilance Controls
- EU Pharmacovigilance Inspection Findings: Training, Competence and Qualified Personnel
- EU Pharmacovigilance Inspection Findings: Data Integrity, Traceability and the Evidence Chain
- EU Pharmacovigilance Inspection Findings: CAPA Effectiveness and Recurrence of Deficiencies
- EU Pharmacovigilance Compliance Monitoring: Detecting Failures Before Inspection
Product Safety and Signal Evaluation
4- Recombinant ADAMTS13: Immunogenicity, Neutralising Antibodies and Loss of Effect
- Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk
- Deoxycholic Acid Injection (Kybella): Development, Safety Evolution and Pharmacovigilance
- Carbidopa/Levodopa: Vitamin B6 Deficiency, Refractory Seizures and Pharmacovigilance
XEVMPD and Article 57
4- Maintaining XEVMPD Through the Product Lifecycle: Variations, Transfers, Renewals, Suspensions and Withdrawals
- XEVMPD Lifecycle Maintenance: Managing Variations, Transfers and Withdrawals
- XEVMPD Data Quality: Common Errors, Validation and Maintenance
- XEVMPD Data Quality: Reconciliation, Completeness and Detecting Hidden Errors